Mesoblast books 60% surge in Ryoncil sales to $35.1M in December 2025 quarter
Mesoblast (ASX:MSB), a global leader in allogeneic cellular therapies for inflammatory diseases, reported a 60% increase in Ryoncil (remestemcel-L-rknd) sales, generating US$35.1 million in gross revenue for the December 2025 quarter.










-640x358.jpg&w=3840&q=75)
